Serial volumetric MRI in Parkinsonian disorders
Identifieur interne : 002C51 ( Main/Corpus ); précédent : 002C50; suivant : 002C52Serial volumetric MRI in Parkinsonian disorders
Auteurs : Edward J. Wild ; Nick C. FoxSource :
- Movement Disorders [ 0885-3185 ] ; 2009.
English descriptors
- KwdEn :
Abstract
Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra‐ and inter‐rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI‐based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22500
Links to Exploration step
ISTEX:8D31798F89627389ED9EE4A060C8AEC61BF31A56Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serial volumetric MRI in Parkinsonian disorders</title><author><name sortKey="Wild, Edward J" sort="Wild, Edward J" uniqKey="Wild E" first="Edward J." last="Wild">Edward J. Wild</name><affiliation><mods:affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Fox, Nick C" sort="Fox, Nick C" uniqKey="Fox N" first="Nick C." last="Fox">Nick C. Fox</name><affiliation><mods:affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D31798F89627389ED9EE4A060C8AEC61BF31A56</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22500</idno><idno type="url">https://api.istex.fr/document/8D31798F89627389ED9EE4A060C8AEC61BF31A56/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002C51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Serial volumetric MRI in Parkinsonian disorders</title><author><name sortKey="Wild, Edward J" sort="Wild, Edward J" uniqKey="Wild E" first="Edward J." last="Wild">Edward J. Wild</name><affiliation><mods:affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Fox, Nick C" sort="Fox, Nick C" uniqKey="Fox N" first="Nick C." last="Fox">Nick C. Fox</name><affiliation><mods:affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009">2009</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S691">S691</biblScope><biblScope unit="page" to="S698">S698</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8D31798F89627389ED9EE4A060C8AEC61BF31A56</idno><idno type="DOI">10.1002/mds.22500</idno><idno type="ArticleID">MDS22500</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>dementia with lewy bodies</term><term>magnetic resonance imaging</term><term>multiple system atrophy</term><term>parkinson's disease</term><term>progressive supranuclear palsy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra‐ and inter‐rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI‐based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Edward J. Wild MRCP</name><affiliations><json:string>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Nick C. Fox MRCP, PhD</name><affiliations><json:string>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>magnetic resonance imaging</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia with lewy bodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>multiple system atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progressive supranuclear palsy</value></json:item></subject><articleId><json:string>MDS22500</json:string></articleId><language><json:string>eng</json:string></language><abstract>Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra‐ and inter‐rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI‐based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>5.992</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1056</abstractCharCount><pdfWordCount>4228</pdfWordCount><pdfCharCount>27983</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>147</abstractWordCount></qualityIndicators><title>Serial volumetric MRI in Parkinsonian disorders</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>S698</last><first>S691</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22500</json:string></doi><id>8D31798F89627389ED9EE4A060C8AEC61BF31A56</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8D31798F89627389ED9EE4A060C8AEC61BF31A56/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8D31798F89627389ED9EE4A060C8AEC61BF31A56/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8D31798F89627389ED9EE4A060C8AEC61BF31A56/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Serial volumetric MRI in Parkinsonian disorders</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: The authors report no conflicts of interest.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Serial volumetric MRI in Parkinsonian disorders</title><author><persName><forename type="first">Edward J.</forename><surname>Wild</surname></persName><roleName type="degree">MRCP</roleName><affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Nick C.</forename><surname>Fox</surname></persName><roleName type="degree">MRCP, PhD</roleName><note type="correspondence"><p>Correspondence: National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, United Kingdom</p></note><affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S691">S691</biblScope><biblScope unit="page" to="S698">S698</biblScope></imprint></monogr><idno type="istex">8D31798F89627389ED9EE4A060C8AEC61BF31A56</idno><idno type="DOI">10.1002/mds.22500</idno><idno type="ArticleID">MDS22500</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra‐ and inter‐rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI‐based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>magnetic resonance imaging</term></item><item><term>parkinson's disease</term></item><item><term>dementia with lewy bodies</term></item><item><term>multiple system atrophy</term></item><item><term>progressive supranuclear palsy</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-10-13">Received</change><change when="2009-01-22">Registration</change><change when="2009">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8D31798F89627389ED9EE4A060C8AEC61BF31A56/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="145"><doi origin="wiley" registered="yes">10.1002/mds.v24.2s</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">S2</numbering></numberingGroup><coverDate startDate="2009">2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="70" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22500</doi><idGroup><id type="unit" value="MDS22500"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-10-13"></event><event type="manuscriptRevised" date="2008-12-09"></event><event type="manuscriptAccepted" date="2009-01-22"></event><event type="firstOnline" date="2009-10-28"></event><event type="publishedOnlineFinalForm" date="2009-10-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S691</numbering><numbering type="pageLast">S698</numbering></numberingGroup><correspondenceTo>National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22500.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="52"></count><count type="wordTotal" number="4634"></count></countGroup><titleGroup><title type="main" xml:lang="en">Serial volumetric MRI in Parkinsonian disorders<link href="#fn1"></link></title><title type="short" xml:lang="en">Serial Volumetric MRI in Parkinsonian Disorders</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Edward J.</givenNames><familyName>Wild</familyName><degrees>MRCP</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Nick C.</givenNames><familyName>Fox</familyName><degrees>MRCP, PhD</degrees></personName><contactDetails><email>nfox@dementia.ion.ucl.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">magnetic resonance imaging</keyword><keyword xml:id="kwd2">parkinson's disease</keyword><keyword xml:id="kwd3">dementia with lewy bodies</keyword><keyword xml:id="kwd4">multiple system atrophy</keyword><keyword xml:id="kwd5">progressive supranuclear palsy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra‐ and inter‐rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI‐based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: The authors report no conflicts of interest.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Serial volumetric MRI in Parkinsonian disorders</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Serial Volumetric MRI in Parkinsonian Disorders</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Serial volumetric MRI in Parkinsonian disorders</title></titleInfo><name type="personal"><namePart type="given">Edward J.</namePart><namePart type="family">Wild</namePart><namePart type="termsOfAddress">MRCP</namePart><affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nick C.</namePart><namePart type="family">Fox</namePart><namePart type="termsOfAddress">MRCP, PhD</namePart><affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology/National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation><description>Correspondence: National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009</dateIssued><dateCaptured encoding="w3cdtf">2008-10-13</dateCaptured><dateValid encoding="w3cdtf">2009-01-22</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">2</extent><extent unit="references">52</extent><extent unit="words">4634</extent></physicalDescription><abstract lang="en">Tracking progression in neurodegenerative diseases is hampered by the limitations of the clinical rating scales, which are seldom linear, suffer from floor and ceiling effects, lack the ability to distinguish symptomatic change from disease modification, and are limited by imperfect intra‐ and inter‐rater reliability. The promise of an era of neuroprotective therapies renders urgent the search for reliable measures of progression. Biomarkers have the potential to enhance several aspects of both therapeutic trials and clinical practice. MRI‐based measures of cerebral volume can provide a surrogate for neuronal loss and several techniques have been applied to elucidate disease processes, aid diagnosis, and enable monitoring of progression in a variety of Parkinsonian disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy and Huntington's disease. We review the approaches to, and findings revealed by, serial volumetric MRI in these disorders. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: The authors report no conflicts of interest.</note><subject lang="en"><genre>Keywords</genre><topic>magnetic resonance imaging</topic><topic>parkinson's disease</topic><topic>dementia with lewy bodies</topic><topic>multiple system atrophy</topic><topic>progressive supranuclear palsy</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>S2</number></detail><extent unit="pages"><start>S691</start><end>S698</end><total>8</total></extent></part></relatedItem><identifier type="istex">8D31798F89627389ED9EE4A060C8AEC61BF31A56</identifier><identifier type="DOI">10.1002/mds.22500</identifier><identifier type="ArticleID">MDS22500</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002C51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:8D31798F89627389ED9EE4A060C8AEC61BF31A56
|texte= Serial volumetric MRI in Parkinsonian disorders
}}
| This area was generated with Dilib version V0.6.23. |  |